iScience (Jan 2022)

The isoquinoline PRL-295 increases the thermostability of Keap1 and disrupts its interaction with Nrf2

  • Sharadha Dayalan Naidu,
  • Takafumi Suzuki,
  • Dina Dikovskaya,
  • Elena V. Knatko,
  • Maureen Higgins,
  • Miu Sato,
  • Miroslav Novak,
  • José A. Villegas,
  • Terry W. Moore,
  • Masayuki Yamamoto,
  • Albena T. Dinkova-Kostova

Journal volume & issue
Vol. 25, no. 1
p. 103703

Abstract

Read online

Summary: Transcription factor Nrf2 and its negative regulator Keap1 orchestrate a cytoprotective response against oxidative, metabolic, and inflammatory stress. Keap1 is a drug target, with several small molecules in drug development. Here, we show that the isoquinoline PRL-295 increased Keap1 thermostability in lysates from cells expressing fluorescently tagged Keap1. The thermostability of endogenous Keap1 also increased in intact cells and murine liver following PRL-295 treatment. Fluorescence Lifetime Imaging–Förster Resonance Energy Transfer (FLIM-FRET) experiments in cells co-expressing sfGFP-Nrf2 and Keap1-mCherry further showed that PRL-295 prolonged the donor fluorescence lifetime, indicating disruption of the Keap1-Nrf2 protein complex. Orally administered PRL-295 to mice activated the Nrf2transcriptional target NAD(P)H:quinone oxidoreductase 1 (NQO1) in liver and decreased the levels of plasma alanine aminotransferase and aspartate aminotransferase upon acetaminophen-induced hepatic injury. Thus, PRL-295 engages the Keap1 protein target in cells and in vivo, disrupting its interaction with Nrf2, leading to activation of Nrf2-dependent transcription and hepatocellular protection.

Keywords